NASDAQ OMX

Covisint Extends Relationship with Ford Motor Company

31.5.2017 23:35 | NASDAQ OMX

Dela

Enables Secure Access to Information and Applications for Global Suppliers

DETROIT, May 31, 2017 (GLOBE NEWSWIRE) -- Covisint Corporation (Nasdaq:COVS) today announced that it has extended its relationship with Ford Motor Company ("Ford").  With this extension, Ford will continue to leverage the Covisint B2B Automotive Exchange.

The Covisint B2B Automotive Exchange currently provides global access to information and applications for more than 615,000 supplier users across 100,000 supplier organizations connected to select global automotive OEMs.  The B2B Automotive Exchange provides global OEMs with the following:

  • Extends the OEMs enterprise to manage external supplier users with single sign-on to critical resources based on user types.
  • Provides delegated administration both for security and access, as well as for content management and collaboration resources.
  • Helps to manage, automate and govern the complex network of people, systems, and devices that need access to resources.
  • Allows authenticated and unauthenticated content to be personalized and presented to users based upon attributes such as location, division and role.
  • Anytime, anywhere 24x7 support with industry-leading service level agreements and availability.

About Covisint Corporation

Covisint is the connected company - we securely connect ecosystems of people, systems and things to enable new service offerings, optimize operations, develop new business models and ultimately enable the connected economy.  Today, we support more than 2,000 organizations and connect to more than 212,000 business partners and customers worldwide.  Learn more at www.covisint.com.

Follow us:

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding Covisint's present and future technology design, architecture, performance and operations which affects the Covisint IoT Platform's market growth and the demand for Covisint's solutions.  Any forward-looking statements contained in this press release are based upon Covisint's historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved.  These forward-looking statements represent Covisint's expectations as of the date of this press release.  Subsequent events may cause these expectations to change, and Covisint disclaims any obligation to update the forward-looking statements in the future except as may otherwise be required by the federal securities laws.  These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially.  Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, Ford Motor Company's ability to non-renew the purchase order or to terminate our contract for convenience.  Further information on potential factors that could affect actual results is included in Covisint's reports filed with the SEC.

Investor Relations Contact
866-319-7659  
investors@covisint.com

Media Contact
Brad Schechter, Vice President, Corporate Marketing
248-483-2097
bschecht@covisint.com

For Sales and Marketing Information 
Covisint Corporation, 26533 Evergreen Road, Suite 500, 
Southfield, MI 48076, 800-229-4125
http://www.covisint.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Covisint Corporation via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52Pressmeddelande

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci

Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00Pressmeddelande

6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future.  Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.

Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France22.6.2017 22:50Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations. Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT. TB  test at a rate of approximately 60 Euros per test. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-r

Standard Lithium Raises $7.4 Million in Oversubscribed Financing22.6.2017 21:49Pressmeddelande

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 22, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that it has completed the private placement of 9,894,785 common shares at a price of $0.75 per share for gross proceeds of $7,421,089.  Interest in the placement far exceeded the expectations of the Company, and the additional amount raised provides the Company with the capital needed to advance its current projects and pursue strategic acquisitions in the lithium sector. "We are extremely pleased with the interest received in this placement, and completion represents a significant milestone for the Company," commented Anthony Alvaro, a director of the Company.  "The strong demand speaks to the growing confidence in our team, projects and futur

IAGC: Plankton Study Speculative and Needs Better Data22.6.2017 16:08Pressmeddelande

Houston, TX, US, June 22, 2017 (GLOBE NEWSWIRE) -- The International Association of Geophysical Contractors (IAGC) released the following statement regarding the publishing of research on the interaction of seismic surveys and zooplankton in Nature: Ecology and Evolution. The IAGC President, Nikki Martin issued the following statement: "While we found the study interesting, we are also troubled by the small sample sizes, the large day-to-day variability in both the baseline and experimental data, and the large number of speculative conclusions that appear inconsistent with the data collected over a two-day period.  Both statistically and methodologically, this project falls short of what would be needed to provide a convincing case for adverse effects from geophysical survey operations.  "Although the initial report is peer-reviewed, it has not been widely accepted by the expert scientific community.  We look forward to discussing this topic further with

Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia22.6.2017 14:30Pressmeddelande

New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 CMC scale-up work for NDA preparation initiated WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the successful completion of a bridging trial to select an improved, gastric-resistant (GR) formulation of MIN-101. The Company plans to use the selected formulation in its upcoming Phase 3 clinical trial, which remains on schedule for initiation in the second half of 2017, as well as for the potential future submission of a New Drug Application (NDA). 

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum